Salarius Pharmaceuticals Inc Stock Price, News & Analysis

Salarius Pharmaceuticals (Nasdaq: SLRX) announced its participation in the Diamond Equity Research Emerging Growth Invitational conference on April 5, 2023. Key executives, including CFO Mark Rosenblum and Dr. Daniela Santiesteban, will present at 11:00 a.m. Eastern time, followed by a Q&A session. Salarius specializes in developing innovative cancer therapies such as seclidemstat, which is undergoing a Phase 1/2 trial for Ewing sarcoma. The company has received fast track and orphan drug designations from the FDA for this candidate. For more details, visit Salarius’ website or register for the webcast using the provided link.

Salarius Pharmaceuticals (SLRX) reported promising preclinical results for its targeted protein degrader SP-3164, showing significant anticancer activity in non-Hodgkin Lymphoma and Multiple Myeloma models. The company is on track to file an IND in the first half of 2023 and expects to initiate clinical trials later this year. Financially, Salarius reported a net loss of $31.6 million for 2022, primarily due to increased R&D expenses and a one-time goodwill impairment of $8.9 million. Cash reserves decreased to $12.1 million as of December 31, 2022, but are projected to fund operations through Q4 2023.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced the acceptance of two abstracts for presentation at the AACR Annual Meeting from April 14-19, 2023. The abstracts focus on the novel molecular glue SP-3164's activity in treating non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). One study shows SP-3164's potential as an orally available treatment for NHL, while another highlights its effectiveness in degrading cancer-promoting proteins in MM, demonstrating superior activity compared to existing therapies. Clinical trials for SP-3164 are anticipated to begin this year, emphasizing its promising role in oncology.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced that Dr. Justine Delgado will present a poster titled “Pre-clinical Investigation of the LSD1 Inhibitor, SP-2577 (seclidemstat) in Small Cell Lung Cancer” at the Keystone Symposia on March 13, 2023. Seclidemstat exhibited notable anti-proliferative effects across various small cell lung cancer (SCLC) cell lines and showed potential synergistic effects when combined with topotecan and Lurbinectedin. The drug is currently in Phase 1/2 trials for multiple cancers, including relapsed Ewing sarcoma. Salarius’ lead candidate has garnered fast track and orphan drug designations from the FDA, highlighting its clinical significance.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced a $1.48 million payment from the Cancer Prevention and Research Institute of Texas (CPRIT), as part of a $16.1 million non-dilutive grant aimed at supporting the development of their drug candidate, seclidemstat, for Ewing sarcoma. This funding increases Salarius’ total disbursement from CPRIT to approximately $16.0 million. The company shared interim data suggesting that seclidemstat, when combined with other treatments, may delay tumor progression. However, the Phase 1/2 clinical trial is currently on partial hold due to a suspected severe adverse reaction, though the company is hopeful for a potential resumption in patient enrollment.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced promising preclinical data on its targeted protein degrader SP-3164 for non-Hodgkin’s lymphomas (NHL). The data demonstrated synergistic effects with rituximab, achieving complete tumor elimination in 50% of treated mice, and superior efficacy compared to standard treatments. The company plans to submit an Investigational New Drug (IND) application for SP-3164 to the FDA and initiate a Phase 1 trial later in 2023. SP-3164, an oral small molecule, utilizes a unique platform to enhance treatment efficacy.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced that Dr. Aundrietta Duncan will present preclinical data on SP-3164 at the Molecular Glue Drug Development Summit from January 24-26, 2023. SP-3164, an oral next-generation molecular glue, aims to stabilize the preferred enantiomer of avadomide, showing promising efficacy in non-Hodgkin's lymphomas. The company plans to submit an Investigational New Drug application and initiate a Phase 1 trial in 2023. SP-3164 has received a composition of matter patent, and previous data indicated strong activity in lymphoma models. The CEO highlighted the importance of molecular glue degraders in targeting previously undruggable proteins.

Salarius Pharmaceuticals (NASDAQ: SLRX) announced the issuance of U.S. Patent No. 11,535,603, protecting its second novel molecular glue, SP-3204, which targets disease-causing proteins for degradation. This expands Salarius' intellectual property portfolio to 16 issued patents across six families, enhancing their targeted protein degradation (TPD) platform. The patent covers SP-3204 through September 2037 and validates the company's commitment to protecting innovative therapies for cancers in need of new treatment options.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announced promising results from an investigator-initiated Phase 1/2 study of seclidemstat combined with azacitidine for patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The study showed a 50% overall response rate among evaluable patients, with no serious adverse events reported. However, enrollment was paused in October due to a suspected unexpected serious adverse reaction in another study. Seclidemstat is being explored as a potential treatment for patients with limited options and has received various FDA designations.